Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04612790 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT04612790: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT04612790 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 67 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04612790, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
Primary Outcome
A responder was defined as a participant who was in complete remission while off OCS for ≥2 months at Week 36.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 3 |
Why NCT04612790 stopped before completion
NCT04612790 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04612790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04612790 about?
NCT04612790 is a clinical study titled "A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.". The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
What is the current status of trial NCT04612790?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2021-03-31. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT04612790?
The interventions under investigation include: Placebo (BIOLOGICAL), Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04612790?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04612790's enrollment target sits among peer trials
67 1796th of 2000 higher than 204 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI